Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Citalopram tablets (adults) - selected U.S. labeling
Product / population
Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.
Renal method
CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Citalopram tablets (adults) - selected U.S. labeling
U.S. product labeling / DailyMed · Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.
Renal method: CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Start 20 mg orally once daily. When needed, increase after at least one week; maximum 40 mg/day. Limit to 20 mg/day in patients older than 60, hepatic impairment, CYP2C19 poor metabolizers, or those taking CYP2C19 inhibitors.
Mild or moderate renal impairment: no dose change is recommended. Pharmacokinetic data are unavailable at CrCl below 20 mL/min. This label supplies no numeric severe-renal or dialysis dose.
RDM31-citalopram-tablets-label-renal · Source locator: 12.3: Patients with Renal Impairment
Selected warnings and limits
Assess QT-prolongation risk and electrolytes; monitor for suicidality and serotonin syndrome. Review MAOI and other interacting drugs before treatment.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.